References
- Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safe-ty of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–7.
- Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-1056.
- Rubin BP, Schuetze SM, Eary JF, et al. Molecular tar-geting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002; 20: 3586–91.
- Mace J, Sybil Biermann J, Sondak V, et al. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002; 95: 2373–9.
- Casali PG, Messina A, Stacchiotti S, et al. Imatinib mesylate in chordoma. Cancer 2004; E-pub. Sept.15.
- Casali PG, Fumagalli E, Messina A, et al. Tumor response to imatinib mesylate in advanced GIST. Proc Am Soc Clin Oncol 2004; 23: Abs. #9028
- Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointesti-nal stromal tumours. Lancet Oncol 2002; 3: 655–64.
- Stroobants S, Goeminne J, Seegers M, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003; 39: 2012-20.
- Blanke C, Joensuu H, Demetri G, et al. Long-term fol-low up of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate. Gastrointestinal Cancers Symposium 2004; Abs. #2.
- Demetri CD, von Mehren M, Blanke CD, et al. Efficacy and safety of Imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347; 472–480.
- Van Oosterom AT, Judson IR, Verweij J, et al. Update of phase I study of imatinib (5TI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002; 38 Suppl 5: S83–87.
- Heinrich MC, Corless CL, Demetri CD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342–9.
- Lynch TJ, Bell DW, Sordella R, et al. Activating muta-tions in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129–39.
- Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose ima-tinib: randomised trial. Lancet. 2004; 364: 1127–34.
- Benjamin RS, Rankin C, Fletcher C, et al. Phase III dose-randomized study of imatinib mesylate (5TI571) for GIST: Intergroup S0033 early results. Am Soc Clin Oncol Proc 2003; 22: Abs. # 3271.
- Fletcher JA, Corless CL, Dimitrijevic S, et al. Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST). Am Soc Clin Oncol Proc 2003; 22: #3275.
- Weisberg E, Griffin JD. Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist Updat 2003; 6: 231–8.
- Tamborini E, Bonadiman L, Greco A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004; 127: 294–9
- Demetri CD, George S, Heinrich MC, et al. Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor 5U11248 in patients (pts) with metastatic gastroin-testinal stromal tumor (GIST) refractory to imatinib mesylate. Am Soc Clin Oncol Proc 2003; 22: Abs. #3273.
- Bauer S, Hartmann JT, Lang H, et al. Imatinib may enable complete resection in previously unresectable or metastatic GIST. Am Soc Clin Oncol Proc 2003; 22: Abs. #9023.